Clinical Trial Update: Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study [Phase 4]

View source ↗

Summary

The document summarizes a completed Phase 4 randomized trial evaluating Myfortic (mycophenolate mofetil) for minimal change nephrotic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Minimal Change Nephrotic Syndrome

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: The University of Hong Kong | Conditions: Nephrosis, Lipoid | Phase 4 | Status: COMPLETED